{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:28Z","timestamp":1786119448075,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/mjt.0b013e3181bdc3d0","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T04:15:25Z","timestamp":1269404125000},"page":"313-322","source":"Crossref","is-referenced-by-count":11,"title":["Cinacalcet for the Treatment of Primary Hyperparathyroidism"],"prefix":"10.1097","volume":"18","author":[{"given":"Melanie L","family":"Dillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A","family":"Frazee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210202","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1383\/medc.2005.33.12.52","article-title":"Hypercalcaemia and primary hyperparathyroidism.","volume":"33","author":"Hatfield","year":"2005","journal-title":"Medicine"},{"key":"R2-9-20210202","first-page":"49","article-title":"Endocr Pract.","volume":"11","year":"2005","journal-title":""},{"key":"R3-9-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7812\/TPP\/07-091","article-title":"Current status and treatment of primary hyperparathyroidism.","volume":"12","author":"Elaraj","year":"2008","journal-title":"Permanente J"},{"key":"R4-9-20210202","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJM200012213432508","article-title":"Hyperparathyroid and hypoparathyroid disorders.","volume":"343","author":"Marx","year":"2000","journal-title":"N Engl J Med"},{"key":"R5-9-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2004.01422.x","article-title":"Primary hyperparathyroidism: new concepts in clinical, desitometric and biochemical features.","volume":"257","author":"Bilezikian","year":"2005","journal-title":"J Intern Med"},{"key":"R6-9-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1385\/BMM:1:1:25","article-title":"Primary hyperparathyroidism: epidemiology and clinical consequences.","volume":"1","author":"Bilezikian","year":"2002","journal-title":"Clin Rev Bone Metab"},{"key":"R7-9-20210202","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2265.2002.01581.x","article-title":"The management of primary hyperparathyroidism.","volume":"57","author":"Davies","year":"2002","journal-title":"Clin Endocrinol"},{"key":"R8-9-20210202","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2165\/00003495-200666170-00004","article-title":"Current pharmacological options for the management of primary hyperparathyroidism.","volume":"66","author":"Vestergaard","year":"2006","journal-title":"Drugs"},{"key":"R9-9-20210202","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMcp032200","article-title":"Asymptomatic primary hyperparathyroidism.","volume":"350","author":"Bilezikian","year":"2004","journal-title":"N Engl J Med"},{"key":"R10-9-20210202","first-page":"423","article-title":"Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism.","volume":"148","author":"Hedback","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"R11-9-20210202","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archsurg.141.6.589","article-title":"Parathyroid surgical failures with sufficient decline of intraoperative parathyroid hormone levels.","volume":"141","author":"Westerdahl","year":"2006","journal-title":"Arch Surg"},{"key":"R12-9-20210202","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3949\/ccjm.75.10.739","article-title":"Using biochemical markers of bone turnover in clinical practice.","volume":"75","author":"Singer","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"R13-9-20210202","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2362.2007.01874.x","article-title":"The role of calcimimetics in the treatment of hyperparathyroidism.","volume":"37","author":"Wuthrich","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"R14-9-20210202","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/0003-4819-100-5-633","article-title":"Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism.","volume":"100","author":"Marcus","year":"1984","journal-title":"Ann Intern Med"},{"key":"R15-9-20210202","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198606053142304","article-title":"Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.","volume":"314","author":"Selby","year":"1986","journal-title":"N Engl J Med"},{"key":"R16-9-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01623394","article-title":"Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report.","volume":"6","author":"Diamond","year":"1996","journal-title":"Osteoporos Int"},{"key":"R17-9-20210202","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/8756-3282(95)91636-L","article-title":"Longitudinal changes of bone mineral density in primary hyperparathyroidism [Abstract].","volume":"16","author":"Guo Cy, Thomas","year":"1995","journal-title":"Bone"},{"key":"R18-9-20210202","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized controlled trial.","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"key":"R19-9-20210202","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.","volume":"160","author":"Orr-Walker","year":"2000","journal-title":"Arch Intern Med"},{"key":"R20-9-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the womens health initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R21-9-20210202","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated estrogens in postmenopausal women with hysterectomy: the womens health initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R22-9-20210202","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","article-title":"Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.","volume":"16","author":"Zanchetta","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R23-9-20210202","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-9-20210202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00019616-200111000-00006","article-title":"Alendronate therapy of primary hyperparathyroidism.","volume":"11","author":"Hassani","year":"2001","journal-title":"Endocrinologist"},{"key":"R25-9-20210202","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R26-9-20210202","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathryoid-related osteoporosis: a 2-year study.","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-9-20210202","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-9-20210202","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-9-20210202","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/8756-3282(91)90016-C","article-title":"Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism.","volume":"12","author":"Torring","year":"1991","journal-title":"Bone"},{"key":"R30-9-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/8756-3282(92)90207-D","article-title":"Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism.","volume":"13","author":"Stone","year":"1992","journal-title":"Bone"},{"key":"R31-9-20210202","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.clinthera.2005.11.015","article-title":"Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism.","volume":"27","author":"Dong","year":"2005","journal-title":"Clin Ther"},{"key":"R32-9-20210202","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1345\/aph.1D108","article-title":"Calcimimetics and the treatment of primary and secondary hyperparathyroidism.","volume":"38","author":"Joy","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R33-9-20210202","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-9-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.","volume":"90","author":"Peacok","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-9-20210202","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","article-title":"Cinacalcet for the treatment of primary hyperparathyroidism.","volume":"57","author":"Sajid-Crockett","year":"2008","journal-title":"Metab Clin Exp"},{"key":"R37-9-20210202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MAJ.0b013e3181379f3e","article-title":"Acute and one-year effects of cinacalcet in patients with persistant primary hyperparathyroidism after unsuccessful parathyroidectomy.","volume":"335","author":"Iglesias","year":"2008","journal-title":"Am J Med Sci"},{"key":"R38-9-20210202","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrin Metab"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0b013e3181bdc3d0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:19:38Z","timestamp":1786040378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201107000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181bdc3d0","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}